MX2008008050A - Suministro transdermico de meptazinol. - Google Patents

Suministro transdermico de meptazinol.

Info

Publication number
MX2008008050A
MX2008008050A MX2008008050A MX2008008050A MX2008008050A MX 2008008050 A MX2008008050 A MX 2008008050A MX 2008008050 A MX2008008050 A MX 2008008050A MX 2008008050 A MX2008008050 A MX 2008008050A MX 2008008050 A MX2008008050 A MX 2008008050A
Authority
MX
Mexico
Prior art keywords
meptazinol
transdermal delivery
increases
disclosed
analgesic relief
Prior art date
Application number
MX2008008050A
Other languages
English (en)
Inventor
Richard Franklin
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of MX2008008050A publication Critical patent/MX2008008050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un sistema de administración para suministrar una sal de meptazinol o precursor de meptazinol que incrementa la biodisponibilidad del meptazinol al proporcionar una cantidad efectiva para alivio analgésico. Una modalidad del sistema de administración es un dispositivo transcutáneo el cual incrementa el flujo de meptazinol en la piel al proporcionar una cantidad efectiva para alivio analgésico. También se describen métodos para proporcionar alivio analgésico.
MX2008008050A 2005-12-21 2006-12-21 Suministro transdermico de meptazinol. MX2008008050A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75335705P 2005-12-21 2005-12-21
US86211406P 2006-10-19 2006-10-19
PCT/US2006/048783 WO2007075883A2 (en) 2005-12-21 2006-12-21 Transdermal delivery of meptazinol

Publications (1)

Publication Number Publication Date
MX2008008050A true MX2008008050A (es) 2009-04-06

Family

ID=38198475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008008050A MX2008008050A (es) 2005-12-21 2006-12-21 Suministro transdermico de meptazinol.

Country Status (15)

Country Link
US (1) US20070224253A1 (es)
EP (1) EP1962817B1 (es)
AR (1) AR058598A1 (es)
AT (1) ATE488229T1 (es)
AU (1) AU2006331596A1 (es)
CA (1) CA2633369A1 (es)
DE (1) DE602006018355D1 (es)
DK (1) DK1962817T3 (es)
EA (1) EA200801575A1 (es)
MX (1) MX2008008050A (es)
PE (1) PE20071163A1 (es)
PT (1) PT1962817E (es)
TW (1) TW200800223A (es)
UY (1) UY30056A1 (es)
WO (1) WO2007075883A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
CA2657435A1 (en) 2006-07-10 2008-07-03 Medipacs, Inc. Super elastic epoxy hydrogel
WO2009073734A2 (en) 2007-12-03 2009-06-11 Medipacs, Inc. Fluid metering device
WO2009092073A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
CN105902482A (zh) * 2008-06-25 2016-08-31 Fe3医学有限公司 用于经皮递送治疗有效量的铁的贴片和方法
US8190252B2 (en) 2009-02-12 2012-05-29 Incube Labs, Llc Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes
US8961492B2 (en) 2009-02-12 2015-02-24 Incube Labs, Llc System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation
US9095503B2 (en) 2009-02-12 2015-08-04 Incube Labs, Llc System and method for biphasic transdermal iontophreotic delivery of therapeutic agents
WO2010093472A2 (en) * 2009-02-12 2010-08-19 Incube Labs, Llc Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
US8423131B2 (en) * 2009-06-26 2013-04-16 Incube Labs, Llc Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use
WO2011032011A1 (en) 2009-09-10 2011-03-17 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
WO2011044175A2 (en) 2009-10-06 2011-04-14 Incube Labs, Llc Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes
US8685038B2 (en) 2009-12-07 2014-04-01 Incube Labs, Llc Iontophoretic apparatus and method for marking of the skin
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
WO2011100376A2 (en) 2010-02-10 2011-08-18 Incube Labs, Llc Methods and architecture for power optimization of iontophoretic transdermal drug delivery
RU2553350C2 (ru) 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
WO2012154704A2 (en) 2011-05-06 2012-11-15 Incube Labs, Llc System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings
US8636696B2 (en) 2011-06-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
EP2847249A4 (en) 2012-03-14 2016-12-28 Medipacs Inc SMART POLYMER MATERIALS WITH EXCESSIVE REACTIVE MOLECULES
WO2014132239A1 (en) 2013-02-28 2014-09-04 Kimberly-Clark Worldwide, Inc. Drug delivery device
CN109621083B (zh) 2013-02-28 2022-03-22 索伦托治疗有限公司 药物递送装置
US10376308B2 (en) 2015-02-05 2019-08-13 Axon Therapies, Inc. Devices and methods for treatment of heart failure by splanchnic nerve ablation
EP3383371B1 (en) 2015-12-09 2024-05-01 Avecho Biotechnology Limited Pharmaceutical formulation
CA3031766A1 (en) 2016-07-29 2018-02-01 Howard Levin Devices, systems, and methods for treatment of heart failure by splanchnic nerve ablation
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
WO2019118976A1 (en) 2017-12-17 2019-06-20 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
JP7334167B2 (ja) 2018-01-26 2023-08-28 アクソン セラピーズ，インク． 内臓神経の血管内アブレーションの為の方法及びデバイス
CN113825464A (zh) 2019-06-20 2021-12-21 阿克松疗法公司 用于内脏神经的血管内消融的方法和装置
US11413090B2 (en) 2020-01-17 2022-08-16 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
CN113491675B (zh) * 2021-07-01 2023-05-23 北京航空航天大学 一种预防瘢痕的微针创口贴及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539277A (en) * 1977-09-16 1979-01-31 Wyeth John & Brother Ltd Hexahydro-1h-azepines
IE55189B1 (en) * 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
DE69939019D1 (de) * 1998-07-07 2008-08-14 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht-irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DE10059415A1 (de) * 2000-11-30 2002-06-06 Gruenenthal Gmbh Verwendung von schwachen Opioiden und gemischten Opioidagonisten/-antagonisten zur Therapie der Harninkontinenz
DE60326354D1 (de) * 2002-08-20 2009-04-09 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
MY141815A (en) * 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer

Also Published As

Publication number Publication date
AR058598A1 (es) 2008-02-13
PT1962817E (pt) 2010-12-13
US20070224253A1 (en) 2007-09-27
EA200801575A1 (ru) 2008-12-30
DE602006018355D1 (de) 2010-12-30
AU2006331596A1 (en) 2007-07-05
EP1962817B1 (en) 2010-11-17
WO2007075883A9 (en) 2007-08-23
ATE488229T1 (de) 2010-12-15
WO2007075883A2 (en) 2007-07-05
TW200800223A (en) 2008-01-01
WO2007075883A3 (en) 2008-01-17
EP1962817A2 (en) 2008-09-03
CA2633369A1 (en) 2007-07-05
PE20071163A1 (es) 2007-11-30
DK1962817T3 (da) 2011-03-07
UY30056A1 (es) 2007-06-29

Similar Documents

Publication Publication Date Title
MX2008008050A (es) Suministro transdermico de meptazinol.
IL245290A0 (en) A medical system for introducing the active substance buprenorphine through the skin
MA34133B1 (fr) Composes pour inhibiteurs de l'immunoproteasome
MY183014A (en) Compounds for enzyme inhibition
EA028821B9 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX2011008289A (es) Tabletas para terapia combinada.
ZA201303965B (en) Transdermal therapeutic system for administering an active substance
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
PL1858496T3 (pl) Poprzezskórny układ terapeutyczny do aplikowania środków przeciwbólowych
ZA200809004B (en) Autodestructive transdermal therapeutic system
PL1865931T3 (pl) Plaster przezskórny
WO2008022128A3 (en) Transdermal delivery of meptazinol
WO2009138734A3 (en) Use of opioid compounds in peripheral pain, wound healing and scar formation
MX2012002952A (es) Agente terapeutico para el dolor cronico.
WO2011042077A8 (de) Transdermale therapeutische systeme enthaltend 4-n-butylresorcin
UA39947U (ru) Применение кристалла CdI2:Pb как сцинтиллятора для регистрации б-частиц
UA110609C2 (uk) Сполуки для інгібування ферменту протеасоми
UA103224C2 (ru) Таблетки для комбинированной терапии
UA40115U (ru) Способ лечения глазного ишемического синдрома
UA56535U (ru) Способ лечения функциональной кисты после резекции яичника
UA60735U (ru) Способ оценки адекватности дозы нейропротектора
UA46514U (ru) Способ местного лечения ограниченной склеродермии